eligibility_summary
Inclusion: Adults ≥19, Korean, newly diagnosed multiple myeloma with suboptimal response after ASCT, enrolled in KarMMa-9 Arm A and treated with idecabtagene vicleucel, able to understand and sign Korea LTFU consent. Exclusion: KarMMa-9 participants who decline Korea LTFU, those unable to receive ide-cel within 9 days post-lymphodepleting chemo if delayed (subject to medical monitor review).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Long-term safety follow-up of idecabtagene vicleucel (ide‑cel) in Korean adults from KarMMa‑9 after ASCT with suboptimal response. Intervention/mechanism: Ide‑cel is an autologous, gene‑modified CAR T‑cell therapy targeting BCMA (TNFRSF17) on malignant plasma cells. Engineered T cells express an anti‑BCMA CAR with 4‑1BB and CD3ζ signaling domains, BCMA binding triggers T‑cell activation, proliferation, cytokine release, and cytotoxic killing (perforin/granzyme) of myeloma cells. Target cells/pathways: BCMA+ plasma cells, BCMA–APRIL/BAFF axis, T‑cell activation pathways (CD3ζ, 4‑1BB costimulation). Context: Parent KarMMa‑9 compared ide‑cel + lenalidomide maintenance vs lenalidomide alone (IMiD, cereblon‑mediated IKZF1/3 degradation, enhances T/NK function).